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Abstract
Background: Epigenetic clocks have been recognized for their precise prediction of chronological age, age-related
diseases, and all-cause mortality. Existing epigenetic clocks are based on CpGs from the Illumina
HumanMethylation450 BeadChip (450 K) which has now been replaced by the latest platform, Illumina
MethylationEPIC BeadChip (EPIC). Thus, it remains unclear to what extent EPIC contributes to increased precision
and accuracy in the prediction of chronological age.
Results: We developed three blood-based epigenetic clocks for human adults using EPIC-based DNA methylation
(DNAm) data from the Norwegian Mother, Father and Child Cohort Study (MoBa) and the Gene Expression Omnibus
(GEO) public repository: 1) an Adult Blood-based EPIC Clock (ABEC) trained on DNAm data from MoBa (n = 1592, age-
span: 19 to 59 years), 2) an extended ABEC (eABEC) trained on DNAm data from MoBa and GEO (n = 2227, age-span: 18
to 88 years), and 3) a common ABEC (cABEC) trained on the same training set as eABEC but restricted to CpGs
common to 450 K and EPIC. Our clocks showed high precision (Pearson correlation between chronological and
epigenetic age (r) > 0.94) in independent cohorts, including GSE111165 (n = 15), GSE115278 (n = 108), GSE132203 (n =
795), and the Epigenetics in Pregnancy (EPIPREG) study of the STORK Groruddalen Cohort (n = 470). This high precision
is unlikely due to the use of EPIC, but rather due to the large sample size of the training set.
Conclusions: Our ABECs predicted adults’ chronological age precisely in independent cohorts. As EPIC is now the
dominant platform for measuring DNAm, these clocks will be useful in further predictions of chronological age, age-
related diseases, and mortality.
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Background
Aging is a biological phenomenon that is characterized by
reduced functional capacity [1, 2]. Because chronological
age is an imperfect surrogate of aging [3–6], the concept of
biological aging that can capture the different rate of func-
tional deterioration across individuals has been suggested
[1]. Given the significance of biological aging, a variety of
predictors of biological age have been constructed based on
known hallmarks of aging [6, 7], including telomere length
[8], metabolic rate [9], DNA methylation (DNAm) [10],
CD4+ and CD8+ T cell ratio [11], proteomic alterations
[12], and gut microbiota [13]. Among these, DNAm-based
estimators of chronological age (referred to as epigenetic
clocks) have garnered the most interest due to their re-
markable precision in estimating chronological age, age-
related diseases, and all-cause mortality [4, 14–18].
Epigenetic age is a linear combination of DNAm levels
at specific CpGs, which are weighted by their respective
coefficients estimated through an epigenetic clock. Most
of the previously published epigenetic clocks (the Han-
num Blood-based clock [19], Horvath Pan-tissue clock
[20], Levine PhenoAge clock [16], and Horvath Skin &
Blood clock [3]) were based on specific CpGs from the
Illumina HumanMethylation450 BeadChip (450 K). This
platform has recently been replaced by the Illumina
MethylationEPIC BeadChip (EPIC). EPIC is a major im-
provement over its predecessor, 450 K (> 450,000 CpGs),
in terms of the number of probes (> 850,000 CpGs) and
the genomic coverage of regulatory elements [21]. To
our knowledge, only one EPIC-based epigenetic clock
has been published (the Alsaleh EPIC clock [22]). This
clock was trained on a relatively small training set and
was not sufficiently validated in independent cohorts.
Thus, it remains unclear to what extent EPIC contrib-
utes to increased precision and accuracy in the predic-
tion of chronological age.
We developed three blood-based epigenetic clocks for
human adults: 1) an Adult Blood-based EPIC Clock
(ABEC) trained on EPIC-derived DNAm data from adult
peripheral blood in a sub-study of the Norwegian
Mother, Father and Child Cohort Study (MoBa) [23]
called the STudy of Assisted Reproductive Technology
(MoBa-START); 2) an extended ABEC (eABEC) trained
on MoBa-START and publicly available DNAm data
from the Gene Expression Omnibus (GEO) with the aim
of improving the performance of ABEC; and 3) a com-
mon ABEC (cABEC) trained on the same training set as
eABEC but restricted to CpGs common to 450 K and
EPIC. The purpose of cABEC was to determine whether
the additional CpGs on EPIC improved predictions of
chronological age. We validated our clocks and the other
published clocks (the Hannum Blood-based clock, Hor-
vath Pan-tissue clock, Levine PhenoAge clock, Horvath
Skin & Blood clock, Alsaleh EPIC clock, and Zhang
clock) in EPIC-derived DNAm data from independent
cohorts, including publicly available DNAm data from
GEO and the Epigenetics in Pregnancy (EPIPREG) study
of the STORK Groruddalen Cohort (STORK) [24].
Results
Peripheral blood-based DNA methylation
We trained an epigenetic clock using elastic net regres-
sion on DNAm data from 1592 adults who were
mothers and fathers in MoBa-START (796 women and
796 men). The chronological age of these adults ranged
from 19 to 59 years (19 to 46 years for women and 19 to
59 years for men). DNAm on these individuals was mea-
sured using EPIC. For the current analyses, we focused
on the 770,586 autosomal CpGs that remained after
quality control (see Methods). Table 1 provides add-
itional details regarding the MoBa-START samples.
Adult blood-based EPIC clock (ABEC)
Figure 1 summarizes our analysis flow.
We developed ABEC using a blood-based DNAm dataset
consisting of adults (training set n = 1592, Table 1, Fig. 1).
We used elastic net regression [32] to select the most pre-
dictive CpGs for chronological age. The resulting regression
comprised 1695 CpGs. The predicted DNAm age was cal-
culated using the following equation:
DNAm Agej ¼ β̂ Interceptð Þ þ Xcg1; jβ̂cg1 þ Xcg2; jβ̂cg2 þ…
þ Xcg1695; jβ̂cg1695;
where DNAm Agej is the epigenetic age of the j th individ-
ual, and Xcgi, j refers to the DNAm level of the j th individ-
ual at the i th CpG site. The estimated intercept and beta
coefficients are provided in Supplementary File 1.
Figure 2 shows the performance of ABEC in the training
set (n= 1592, Fig. 2a) and the test set (n= 424, Fig. 2b). The
prediction precision was quantified using the Pearson correl-
ation coefficient (r) between DNAm age and chronological
age. The prediction accuracy was quantified using the me-
dian absolute deviation (MAD) between DNAm age and
chronological age. ABEC showed high precision and accur-
acy in both of the training (r = 0.999, MAD=0.14, Fig. 2a)
and test set (r = 0.95, MAD=1.13, Fig. 2b). The red line in
Fig. 2a and b represents a perfect correlation between
chronological age and DNAm age, and the dotted line refers
to the regression of the predicted DNAm age on chrono-
logical age.
Despite its overall high precision, ABEC slightly
underestimated the age of the older individuals, particu-
larly those above 45 years of age (Fig. 2c, d). This bias is
expected given that the MoBa-START dataset is a preg-
nancy cohort with few individuals older than 45 years. In
addition, most individuals aged 45 years or older were
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males, which may introduce a sex-bias in the prediction
of chronological age.
Extended adult blood EPIC clock (eABEC)
To reduce the underestimation bias and improve the
precision of ABEC among older individuals in the
MoBa-START dataset, we developed an extended ABEC
(eABEC) by adding a publicly available DNAm dataset,
GSE116339 (n = 635) [25], from the GEO data repository
(https://www.ncbi.nlm.nih.gov/geo/) [33] to the original
training set for ABEC (Fig. 3). This increased the total
sample size of the new training set to 2227. Elastic net
regression was used in the same manner as for ABEC
above, and for this training set, the number of selected
CpGs was 1791.
We validated eABEC in an extended test set consisting
of the test set for ABEC and two independent cohorts
(GSE111165 and GSE115278) from GEO. We selected
these GEO datasets because they were EPIC-derived
blood-based DNAm data with a wide age span (20 to 70
years). The inclusion of GSE116339 substantially im-
proved the prediction in individuals aged 45 years and
above (Fig. 3a, b), but there was a slight underestimation
of age among individuals aged 65 years or older in both
the training and test set (Fig. 3c, d).
Advantage of EPIC in developing epigenetic clocks
One major difference between our epigenetic clocks
(ABEC and eABEC) and the previously published clocks
was the use of EPIC for the training set. The training set
of the other epigenetic clocks was mostly based on 450
K, except for the Horvath Skin & Blood clock which
used both 450 K and EPIC-derived DNAm data. To as-
sess whether EPIC-derived DNAm data yield a more ac-
curate and precise clock, we trained a third epigenetic
clock using the same training set as for eABEC but using
only the 397,473 autosomal CpG sites that are in com-
mon between EPIC and 450 K. We refer to this third
clock as ‘common’ ABEC (cABEC) hereafter. Elastic net
regression selected 1892 CpG sites.
Table 1 Description of the peripheral whole-blood-derived DNAm data on the EPIC platform
Cohort Tissue type Platform GEO submitter N Normalization
Methoda
Probe exclusion
Criteriab
Age range
(years)
ABEC
Training data
MoBa-STAR
T
Peripheral whole
blood
EPIC – 1592 BMIQ SC, CH, DP, SNP 19–59
Test data
MoBa-STAR
T
Peripheral whole
blood
EPIC – 424 BMIQ SC, CH, DP, SNP 20–58
eABEC
Training data
MoBa-STAR
T
Peripheral whole
blood
EPIC – 1592 BMIQ SC, CH, DP, SNP 19–59
GSE116339 Peripheral whole
blood
EPIC Curtis et al. [25] 635 Noob SC 23–88
Test data
MoBa-STAR
T
Peripheral whole
blood
EPIC – 424 BMIQ SC, CH, DP, SNP 20–58
GSE111165 Peripheral whole
blood
EPIC Shinozaki et al.
[26]
15 Noob SC 24–61
GSE115278 Peripheral whole
blood
EPIC Arpon et al. [27] 108 Noob SC 19–66
Other test data
EPIPREG Peripheral whole
blood
EPIC – 470 FunNorm SC, CH, DP, SNP 19–42
GSE132203 Peripheral whole
blood
EPIC Kilaru et al. [28] 795 Noob SC 18–76
a Pre-processing method for quantifying DNAm levels in the range of 0 to 1
Noob Normal-exponential out-of-band [29]
BMIQ Beta-mixture quantile dilation [30]
FunNorm Functional normalization [31]
b Probe exclusion criteria
SC Sex chromosome, CH cross-hybridizing, DP detection P-value < 0.01 and SNP single-nucleotide polymorphism
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cABEC showed a high prediction performance, similar
to eABEC (Supplementary File 2, S-Figure 1). The preci-
sion metric (r) of cABEC was identical to that of eABEC.
However, compared to eABEC, the accuracy of cABEC in
the test set was slightly diminished (MAD= 1.25→ 1.3).
We hypothesized that the denser EPIC array might be
beneficial in developing an epigenetic clock with a
smaller training set. To address this point, two types of
epigenetic clocks (one using all the CpGs on EPIC and
the other using the CpGs common to EPIC and 450 K)
were trained on random subsets of the training set of
eABEC and validated in the test sample of eABEC (see
Methods for further details). Both types of epigenetic
clocks showed a remarkable improvement in precision
and accuracy as the sample size of the training set in-
creased (Fig. 4). However, across all the reduced training
sets, the epigenetic clock based on all the CpGs on EPIC
did not outperform the other clock based on the CpGs
common to EPIC and 450 K (Fig. 4). This indicates that
the additional CpGs on EPIC do not enhance the accur-
acy or precision of the epigenetic clocks when the train-
ing set is reduced.
Validation of ABECs and other epigenetic clocks
Using an independent cohort from GEO (n = 123), we
evaluated the performance of ABEC, eABEC, and cABEC
against six published epigenetic clocks: the Hannum
Blood-based clock [19], Horvath Pan-tissue clock [20],
Levine PhenoAge clock [16], Horvath Skin & Blood clock
[3], Alsaleh EPIC clock [22], and Zhang clock [34]. The in-
dependent test set consisted of GSE111165 [26] and
GSE115278 [27] from the GEO database (see Table 1 for
details). None of these GEO datasets have previously been
used to train any epigenetic clocks.
Figure 5 summarizes the results of epigenetic age pre-
diction by ABEC, eABEC, cABEC, and the six published
epigenetic clocks mentioned above. Our eABEC and the
Zhang clock showed the highest precision (r = 0.96),
followed by ABEC (r = 0.95), cABEC (r = 0.95), the Hor-
vath Skin & Blood clock (r = 0.94), and the Hannum
Blood-based epigenetic clock (r = 0.87). The 95% confi-
dence intervals of the r values can be found in Supple-
mentary File 2 (S-Table 1). Here, we note that only the
precision metric (r) was presented in Fig. 5 because the
dots in the scatter plots could deviate systematically
from the 45-degree line (so-called systematic offset) but
still form a very tight prediction, e.g., panel (D) in Fig. 5.
In such cases where high precision and relatively low ac-
curacy are present, the systematic offset can be cali-
brated using a linear transformation, or, if necessary, a
non-linear transformation.
An important distinction of ABECs from the other pub-
lished clocks is that they are based on an ethnically homo-
geneous training set (MoBa-START and GSE116339
comprised individuals of European ancestry). We vali-
dated ABEC, eABEC, cABEC, and the other published epi-
genetic clocks in the EPIC-derived blood-based DNAm
data from EPIPREG (n = 470; 305 European women and
165 South Asian women, Fig. 6), a sub-study of the
STORK Groruddalen Cohort [24]. ABEC, eABEC, cABEC,
the Horvath Skin & Blood clock, and Zhang clock showed
the highest precisions (r > 0.9). More interestingly, eABEC
Fig. 1 Analysis flow. MoBa-START adults were randomly assigned to a training and a test set
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showed that the epigenetic age acceleration (EAA; resid-
uals from the regression of DNAm age on chronological
age) was higher in South Asian women than in Norwegian
women (+ 0.51 years, P = 0.0015, Supplementary File 2, S-
Figure 2A). EAA derived by the Alsaleh EPIC clock was
also elevated in South Asians compared to Norwegians (+
0.25 years, P = 4E-04, Supplementary File 2, S-Figure 2B).
However, EAAs derived by ABEC, cABEC, and the other
published clocks did not show any difference between the
two groups.
Given that ABEC, eABEC, and cABEC were trained on
the ethnically homogeneous training set of Europeans,
they may be sub-optimal for predicting chronological
age in other ethnicities. To explore this further, we ap-
plied ABEC, eABEC, cABEC, and the other published
epigenetic clocks to a GEO dataset comprising African
Americans (GSE132203 [28]; n = 795, Supplementary
File 2, S-Figure 3). All the clocks, except for the Alsaleh
EPIC clock, showed high correlations between chrono-
logical age and epigenetic age (r > 0.86). The 95%
Fig. 2 Chronological age estimation by ABEC. a Scatter plot of chronological age against DNAm age estimated by ABEC in the training set. b
Scatter plot of chronological age against DNAm age estimated by ABEC in the test set. c Residual plot in the training set. d Residual plot in the
test set. The red line in panels (a) and (b) represents a perfect correlation between chronological age and DNAm age, and the dotted line is the
regression of DNAm age on chronological age
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confidence intervals of the r values can be found in Sup-
plementary File 2 (S-Table 1). eABEC, cABEC, and the
Zhang clock showed the highest r of 0.96, and ABEC
and the Horvath Skin & Blood clock showed the second-
highest r of 0.95.
Discussion
We developed precise epigenetic clocks (ABEC and
eABEC) using blood-based DNAm data from EPIC. Our
epigenetic clocks showed a more precise chronological
age prediction than existing blood-based epigenetic
clocks (e.g., the Hannum Blood-based clock and Horvath
Skin & Blood clock; Fig. 5). The reason for the higher
precision is more likely due to the large training set (n =
2227, Table 1) and the wide age-span of the samples (19
to 88 years for the training set of eABEC, Table 1),
which is consistent with the findings by Zhang and col-
leagues [34]. Compared to eABEC, both Hannum Blood-
Fig. 3 Chronological age estimation by eABEC. a Scatter plot of chronological age against DNAm age estimated by eABEC in the extensive
training set. b Scatter plot of chronological age against DNAm age estimated by eABEC in the test set. c Residual plot in the training set. d
Residual plot in the test set. The red line in panels (a) and (b) represents a perfect correlation between chronological age and DNAm age, and
the dotted line is the regression of DNAm age on chronological age
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based clock and Horvath Skin & Blood clock were
trained on fewer samples (n = 656 and n = 896, respect-
ively) that had a wider age-span (19 to 101 years and 0
to 94 years, respectively) [3, 19]. Other clocks (the Hor-
vath Pan-tissue clock and Levine PhenoAge clock) may
not be directly comparable to eABEC for chronological
age prediction. For instance, the Horvath Pan-tissue clock
was designed to measure epigenetic aging not only in
blood but in multiple tissues [20], and the Levine Pheno-
Age was designed to predict phenotypic age (estimated
using 10 clinical biomarkers, e.g., albumin, creatinine,
serum glucose, and seven others) based on DNAm [16].
To develop eABEC, we added GSE116339 to the train-
ing set of ABEC. GSE116339 is from a study by Curtis
et al. [25] that used EPIC to measure DNAm in periph-
eral blood samples collected from 658 individuals of
European ancestry (638 non-Hispanic and 20 Hispanic)
in Michigan, USA. These individuals had been exposed
to the endocrine-disrupting chemical polybrominated bi-
phenyl when an agricultural accident introduced it into
the food supply in the 1970s. We selected 635 individ-
uals from the control group whose total PBB (PBB-153,
PBB-101, PBB-77, and PBB180) exposure was lower than
5 pg/ml. The distribution of the total PBB exposure was
highly right-skewed.
The high precision of eABEC cannot be attributed
solely to the use of the EPIC platform as the additional
413,743 CpGs on EPIC did not improve age prediction
noticeably (Fig. 4). Although the 1791 CpGs selected by
eABEC included 1084 CpGs that only exist on EPIC,
eABEC did not outperform cABEC that used the CpGs
common to 450 K and EPIC. This indicates that 226,915
probes (out of 413,743) that are designed to cover regula-
tory regions (DNase proximal/distal [35] and FANTOM5
[36]) did not increase the precision of the epigenetic
clocks significantly [21]. Yet, Pidsley et al. [21] reported
that probes on EPIC cover 58% of FANTOM5 enhancers,
7% of distal, and 27% of proximal ENCODE regulatory re-
gions, suggesting that the coverage of regulatory regions is
still low. Thus, it is difficult to dismiss the possibility that
other regulatory CpGs not currently included on EPIC
might improve age prediction.
Underestimation and overestimation of epigenetic
clocks should be carefully assessed using residual plots
instead of scatter plots. As we regressed chronological
age on DNAm levels (chronological age = DNAm levels
+ error), a scatter plot that displays chronological age on
the x-axis and DNAm age on the y-axis may lead to the
misconception that DNAm age is overestimated in the
oldest age group and underestimated in the youngest
age group (Supplementary File, S-Figure 4). In contrast,
residual plots that display DNAm age on the x-axis and
residuals (DNAm age minus chronological age) on the y-
axis would enable a fair evaluation of prediction models.
The strength of the current scatter plots lies in the
visualization of EAA (the residuals of the regression of
Fig. 4 Comparison of precision and accuracy between a clock based on the CpGs common to 450 K and EPIC and a clock on all the CpGs on
EPIC. a Scatter plot of the Pearson correlation (r) in the test set against the sample size of the training set. b Scatter plot of MAD in the test set
against the sample size of the training set. In panel (a), we fit the smoothing splines of the Fisher’s Z-transformed r values on the sample size,
derived the confidence intervals, and inverse-transformed them. In panel (b), we fit the smoothing splines of MAD values on the sample size
without transformation. The black dots refer to the clock based on the CpGs common to 450 K and EPIC, and the red dots refer to the clock
based on all the CpGs on EPIC
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DNAm age on chronological age; i.e., the vertical distance
between each dot and the dotted line in Figs. 2 and 3).
Our clocks, particularly eABEC, showed a system-
atic underestimation in older subjects, as was the case
with the Horvath Pan-tissue clock and Hannum
Blood-based clock in GSE132203 [37]. The systematic
underestimation may be corrected by 1) adding more
DNAm data of older subjects to the training set or 2)
calibrating epigenetic clocks using a non-linear trans-
formation (e.g., piecewise cubic regression (with a
knot at 70) or smoothing spline of chronological age
on DNAm age). However, we could not add more
EPIC-derived DNAm data from older subjects (prefer-
ably subjects of European ancestry aged 70 to 80
years) to the training set for eABEC. We note that
the underestimation in older subjects can cause EAA
Fig. 5 Chronological age estimation by ABEC, eABEC, and the other published epigenetic age estimators. a ABEC, b eABEC, c Hannum Blood-
based clock, d Horvath Pan-tissue clock, e Levine PhenoAge clock, f Horvath Skin & blood clock, g Alsaleh Blood-based EPIC clock (the stepwise
regression), and h Zhang clock (elastic net regression). The red line in the panels represents a perfect correlation between chronological age and
DNAm age, and the dotted line is the regression of DNAm age on chronological age
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to be dependent on chronological age. Therefore, for
other researchers who are interested in the associ-
ation between EAA and a given phenotype, we rec-
ommend redefining EAA (e.g., regressing DNAm age
on chronological age using a piecewise cubic regres-
sion or a smoothing spline rather than an ordinary
linear regression) so that EAA is independent of
chronological age.
Our eABEC may result in subtle differences in EAA
across different ethnic groups, e.g., Supplementary
File 2, S-Figure 2A. A hypothesis explaining this bias
is that the CpGs included in eABEC may be located
near SNPs with a low minor allele frequency [38].
The SNPs may influence the DNAm level at the
CpGs if the minor allele frequencies at the SNPs dif-
fer across ethnicities. To address this point, we added
Fig. 6 Application of ABEC, eABEC, and other epigenetic clocks to DNAm data in the EPIPREG sub-study of the STORK Groruddalen cohort. The
title of each panel displays the overall r as well as the ethnicity-specific r. EUR indicates the r between chronological age and DNAm age in 305
women of European ancestry, whereas SAS refers to the r between chronological age and DNAm age in 165 women of South Asian ancestry
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SNP annotations generated by Zhou et al. [38] and
McCartney et al. [39] to Supplementary File 1.
Conclusion
Three blood-based epigenetic clocks were developed to esti-
mate adults’ chronological age using EPIC-derived DNAm
data. The precision of these clocks was high (r > 0.94) when
validated in independent cohorts. The high level of precision
was not explained by the broader genomic coverage of EPIC
(> 850,000 CpG sites) but rather by the large training set
(n= 2227) with a wide age-span (19 to 88 years).
Methods
Study population
MoBa is a nationwide pregnancy cohort study in which
approximately 95,000 mothers, 75,000 fathers, and 114,
000 children were recruited from 1998 to 2008 across
Norway [23]. The participants completed a series of ques-
tionnaires that are also linked to information from the
Medical Birth Registry of Norway [23]. Peripheral whole-
blood samples were collected from the mothers at the
17th week of gestation and at birth and from the fathers at
the 17th week of gestation. Cord-blood samples were col-
lected from newborns at birth [40, 41]. The precise
chronological age in days at blood draw was calculated for
the fathers and mothers. Further details on MoBa have
been described in previous publications [23, 40–42]. We
used data from a sub-study of MoBa (MoBa-START) with
blood-based DNAm data on 2016 adults (mothers and fa-
thers who were randomly selected among complete
mother-father-newborn trios in MoBa).
GSE116339 is an epigenome-wide association study
(EWAS) of polybrominated biphenyl in peripheral blood
[25]. GSE111165 explored the difference in genome-
wide DNAm between brain and peripheral tissues (buc-
cal, saliva, and blood) from epilepsy patients [26].
GSE115278 is an EWAS of insulin resistance, obesity,
and metabolic complications [27, 43–45]. GSE132203
examined the association between DNAm and psychi-
atric or stress-related symptoms [28].
EPIPREG is nested within the STORK Groruddalen
Cohort study (a population-based cohort, n = 823, [24]).
EPIPREG quantified DNAm in white blood cells, col-
lected at the 28th week of gestation, from 480 women
(312 of European ancestry and 168 of South Asian an-
cestry), using EPIC. In this study, we focused on 470
women (305 of European ancestry and 165 of South
Asian ancestry) after excluding eight samples with low
quality and two samples with an absolute EAA larger
than 15 years. Further details of EPIPREG are described
in Supplementary File 3 (S-Figure 7).
The age distributions of all the individuals included in
the training and test sets can be found in Supplementary
File 2 (S-Figure 5 and 6).
Pre-processing of DNA methylation
For MoBa-START, 500 nanograms of DNA stored in
the MoBa Biobank (see Paltiel et al. [41] for further de-
tails of the storage of the biological samples) were
shipped to LIFE & BRAIN GmbH (Bonn, Germany).
The samples were bisulfite converted and processed
using the EZ-96DNA methylation-Lightning™MagPrep
kit (Zymo Research, Irvine, USA) according to the man-
ufacturer’s instructions. The raw iDAT files were
imported and processed using the RnBeads R package
[46]. 44,210 probes with cross-hybridization [39], high
detection p-value (> 0.01), and 16,117 probes near
single-nucleotide polymorphisms (filtering.snp = “3”)
were excluded. The data were run in four batches and
the exclusion criteria for removing probes were applied
to each batch separately. Probes that were excluded from
one batch were removed from all batches. The DNAm
signals at the remaining probes were control-normalized
and corrected for background noise using the wm.nasen
and methylumi.noob options. Additionally, among a total
of 2034 non-replicated samples, we excluded 18 samples
that displayed low signal intensities and deviated (out-
liers) from the clusters formed by principal component
analysis. The two probe chemistries (Type I and Type II
probes) were normalized using Beta-mixture quantile
normalization (BMIQ, [30]) using the wateRmelon R
package [47]. In summary, the number of remaining
probes was 790,213 (770,586 from autosomes and 19,
627 from sex-chromosomes).
For the DNAm data from GEO, we downloaded the
iDAT files and used normal-exponential out-of-band
(Noob, [29]) normalization in the minfi R package [48].
For the DNAm data from EPIPREG, we performed func-
tional normalization (FunNorm, [31]) using the meffil R
package [49]. Further details of the DNA extraction and
quality control process of EPIPREG can be found in
Supplementary File 3.
Elastic net regression
Penalized regressions (glmnet R package [50]) were used
to develop the three ABECs. Chronological age in days
was regressed on 770,586 autosomal CpGs that remained
after quality control. The mixing parameter (alpha) was
set to 0.5 and the shrinkage parameter (lambda) leading to
the minimum mean square error was selected after 10-
fold cross-validation in the training set. Supplementary
File 3 (S-Figure 8) includes cross-validation curves for
lambda and alpha values. ABEC, eABEC and cABEC se-
lected 1695 CpG sites (lambda = 0.02884886), 1791 CpG
sites (lambda = 0.05281471), and 1892 CpG sites
(lambda = 0.0438477), respectively. Supplementary File 1
lists these CpG sites, their corresponding coefficients for
ABEC, eABEC, and cABEC, and SNP annotations gener-
ated by Zhou et al. [38] and McCartney et al. [39].
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Comparison between EPIC-CpG clock and common CpG
clock
The implementation resembles bootstrapping conceptually.
For each of the reduced sample sizes (n = 100, 125, 156,
194, 243, 303, 378, 472, 589, 735, 918, 1145, 1430 and 1784;
the determination of these values is detailed in Supplemen-
tary File 3), we first constructed five training sets by ran-
domly selecting subjects from the full training set of
eABEC (n = 2227). We made the sequence of the reduced
sample sizes denser around 100 and sparser around 2227
because epigenetic clocks gradually improved their preci-
sion and accuracy when the training set was larger than
1145. On each training set, we trained two types of epigen-
etic clocks: one using all the CpGs on EPIC and the other
using the CpGs common to EPIC and 450 K. Next, we vali-
dated these clocks in the test set of eABEC (n = 485) and
calculated r and MAD accordingly. The mgcv R package
[51] was used to fit the smoothing splines in Fig. 4. Particu-
larly, in Fig. 4a, we fit the smoothing splines of the Fisher’s
Z-transformed r values (FðrÞ ¼ 0:5 logð 1þr1 − rÞ) on the sam-
ple size, derived the confidence intervals and inverse-
transformed them.
Availability of epigenetic clocks
The estimated intercepts and coefficients for ABEC,
eABEC, and cABEC can be found in Supplementary File 1.
The ABECs can be readily applied to any DNAm data
using the following procedure: 1) generate a matrix of
beta values (n individuals by p CpG sites) using a back-
ground correction method, e.g., Noob (preferably) with-
out any batch adjustment (Supplementary File 3), 2)
select the CpG sites for the ABECs (Supplementary
File 1) out of the matrix of beta values, 3) calculate the
linear combination of the beta values at the selected
CpG sites, and 4) add the estimated intercept (Supple-
mentary File 1) to the linear combination.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12864-020-07168-8.
Additional file 1. This file includes CpG sites for ABEC, eABEC, and
cABEC, their corresponding coefficients, overlap with the other published
clocks, genomic locations, neighboring genes, presence in the Illumina
HumanMethylation450K and 27 K array, and the SNP annotations
generated by Zhou et al. [38] (with the suffix of “Zhou”) and McCartney
et al. [39] (with the suffix of “McCartney”).
Additional file 2. This file includes 1) a figure displaying the age
prediction of cABEC, 2) a table containing the bootstrapped 95%
confidence intervals for the r values in Figs. 4, 5 and 6) figures displaying
the age prediction of the ABECs and the other published clocks in EPIP
REG and GSE132203, 4) a figure illustrating the regression-to-the-mean ef-
fect and 5) histograms displaying the age distribution of individuals in
each cohort.
Additional file 3. This file includes 1) further details (sample selection,
DNA extraction, and quality control) of EPIPREG, 2) cross-validation curves
of mean squared error over lambda and alpha values for eABEC, 3)
determination of the reduced sample sizes for Fig. 4, and 4) further infor-
mation regarding batch adjustment in developing the ABECs.
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